News

The agreement, whose specific terms were not disclosed, is subject to Laurantis gaining approval for Phase I trial that is scheduled to begin in 2013. Lymfactin leverages an

The REGARD trial, one of the two ramucirumab Phase III studies in gastric cancer, compared ramucirumab and best supportive care with placebo and best supportive care as a

Sigma Life Science has applied its exclusive CompoZr Zinc Finger Nuclease technology to the ADME-Tox field to create proprietary cell-based assays for drug candidate screening. Sigma’s new single

The present labeling update has been granted based on Baraclude study in African-American patients and study in post-liver transplant recipients. Baraclude, a nucleoside analogue has received approval by

The approval is the result of Watson’s agreement to a proposed consent order to divest certain products as a condition to obtaining FTC approval. With the approval the

PolyPEG , a patented polymer increases the half-life in the body of therapeutic proteins to which it is bound. As part of the collaboration, the properties of different

The platform, which is stable and non-lytic protein expression, will complement the existing capabilities in protein vaccine expression at the Jenner Institute, University of Oxford. The solution will

The NOA covers the FDA-approved RAYOS, which uses the company’s proprietary Geoclock technology, for the treatment of various diseases including rheumatoid arthritis (RA). In addition, the drug is

The SqiDlite system, which can run on the company’s SqiDworks microarray platform, integrates fluidics, washer, dryer, scanner and analyzing functions in a user-friendly bench-top footprint. SQI Diagnostics CEO